SCHEMBL4976546 — predicted protein targets

Predicted protein targets (top 18)

	gene	UniProt	supporting neighbours	confidence
▸	KDR	P35968	13/20	0.67

▸	FLT1	P17948	7/20	0.67

▸	KIT	P10721	3/20	0.67

▸	ABL1	P00519	2/20	0.67

▸	CSF1R	P07333	2/20	0.67

▸	PDGFRB	P09619	2/20	0.67

▸	FLT4	P35916	2/20	0.67

▸	EGFR	P00533	1/20	0.67

▸	IGF1R	P08069	1/20	0.60

▸	FGFR1	P11362	1/20	0.60

▸	TEK	Q02763	1/20	0.60

▸	BRAF	P15056	1/20	0.58

▸	MEN1	O00255	1/20	0.55

▸	KMT2A	Q03164	1/20	0.55

▸	RXFP1	Q9HBX9	2/20	0.54

▸	MAPT	P10636	1/20	0.47

▸	SMN1; SMN2	Q16637	1/20	0.47

▸	LRRK2	Q5S007	1/20	0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
SCHEMBL4978310	0.85	KDR (0.71)	KDRFLT1KITABL1CSF1R
SCHEMBL4982146	0.85	KDR (0.71)	KDRFLT1KITABL1CSF1R
SCHEMBL4977683	0.84	KDR (0.71)	KDRFLT1KITABL1CSF1R
SCHEMBL4982167	0.83	KDR (0.71)	KDRFLT1KITABL1CSF1R
SCHEMBL4981491	0.83	KDR (0.72)	KDRFLT1KITABL1CSF1R
SCHEMBL4976779	0.83	KDR (0.71)	KDRFLT1KITABL1CSF1R
SCHEMBL4976158	0.83	KDR (0.67)	KDRFLT1KITABL1CSF1R
SCHEMBL4977490	0.83	KDR (0.80)	KDRFLT1KITABL1CSF1R
SCHEMBL27485937	0.82	KDR (0.70)	KDRFLT1KITABL1CSF1R
SCHEMBL4983660	0.82	KDR (0.66)	KDRFLT1KITABL1CSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
US-20040198782-A1	N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	ALTMANN KARL-HEINZ (CH)	2004-10-07	—	—	US	claimed
US-20030064992-A1	N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	ALTMANN KARL-HEINZ (CH)	2003-04-03	—	—	US	claimed
US-6448277-B2	ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS	NOVARTIS AG (CH)	2002-09-10	—	—	US	claimed
US-20020019414-A1	N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	NOVARTIS AG (CH)	2002-02-14	—	—	US	claimed
CN-1331680-A	N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors	NOVARTIS AG (CH)	2002-01-16	—	—	CN	claimed
US-20080085902-A1	Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent	BOLD GUIDO	2008-04-10	—	—	US	disclosed
US-20060074112-A1	N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	ALTMANN KARL-HEINZ	2006-04-06	—	—	US	disclosed
US-7002022-B2	N-Aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF	NOVARTIS AG (CH)	2006-02-21	—	—	US	disclosed
US-6878720-B2	VEGF receptor tyrosine kinase inhibitors	NOVARTIS AG (CH)	2005-04-12	—	—	US	disclosed
US-20040198782-A1	N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	ALTMANN KARL-HEINZ (CH)	2004-10-07	—	—	US	disclosed
CN-1152014-C	N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors	��˹��ŵ��	2004-06-02	—	—	CN	disclosed
US-20030064992-A1	N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	ALTMANN KARL-HEINZ (CH)	2003-04-03	—	—	US	disclosed
US-6448277-B2	ANTITUOR AGENTS, ANTICARCINOGENIC AGENTS	NOVARTIS AG (CH)	2002-09-10	—	—	US	disclosed
US-20020019414-A1	N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	NOVARTIS AG (CH)	2002-02-14	—	—	US	disclosed
CN-1331680-A	N-aryl (thio) anthranilic acid amide derivatives, their prepn. and their use as VEGF receptor tyrosine kinase inhibitors	NOVARTIS AG (CH)	2002-01-16	—	—	CN	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20080085902-A1	Combination Of A Vegf Receptor Inhibitor Or With A Chemotherapeutic Agent	VEGFA, FLT1, FLT4	KDR 4/4885FLT1 2/4885KIT 95/4885
US-20030064992-A1	N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	AXL, TYRO3, NR2E3	KDR 4/4885FLT1 6/4885KIT 1200/4885
US-20060074112-A1	N-aryl (thio) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	NR2E3, AXL, FLT1	KDR 6/4885FLT1 3/4885KIT 1240/4885
US-20020019414-A1	N-aryl(thio)anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	AXL, TYRO3, KDR	KDR 3/4885FLT1 6/4885KIT 1055/4885
US-20040198782-A1	N-aryl (THIO) anthranilic acid amide derivatives, their preparation and their use as VEGF receptor tyrosine kinase inhibitors	AXL, TYRO3, NR2E3	KDR 4/4885FLT1 6/4885KIT 1176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.